Silva Anna Jéssica Duarte, Rocha Crislaine Kelly da Silva, de Freitas Antonio Carlos
Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil.
Genome Laboratory, Department of Biology, Federal Rural University of Pernambuco, Recife 52171-900, Brazil.
Pharmaceutics. 2022 Dec 14;14(12):2792. doi: 10.3390/pharmaceutics14122792.
In the context of vaccine development, improving antigenic presentation is critical for the activation of specific immune responses and the success of immunization, in addition to selecting an appropriate target. In this sense, different strategies have been developed and improved. Among them is the use of yeast cells as vehicles for the delivery of recombinant antigens. These vaccines, named whole yeast vaccines (WYVs), can induce humoral and cellular immune responses, with the additional advantage of dispensing with the use of adjuvants due to the immunostimulatory properties of their cell wall components. However, there are some gaps in the methodologies for obtaining and validating recombinant strains and vaccine formulations. The standardization of these parameters is an important factor for WYVs approval by regulatory agencies and, consequently, their licensing. This review aimed to provide an overview of the main parameters to consider when developing a yeast-based vaccine, addressing some available tools, and highlighting the main variables that can influence the vaccine production process.
在疫苗研发背景下，除了选择合适的靶点外，改善抗原呈递对于激活特异性免疫反应和免疫接种的成功至关重要。从这个意义上说，已经开发并改进了不同的策略。其中包括使用酵母细胞作为重组抗原递送的载体。这些疫苗被称为全酵母疫苗（WYV），可以诱导体液免疫和细胞免疫反应，由于其细胞壁成分的免疫刺激特性，还具有无需使用佐剂的额外优势。然而，在获得和验证重组菌株及疫苗配方的方法上存在一些差距。这些参数的标准化是监管机构批准WYV并因此发放许可证的重要因素。本综述旨在概述开发基于酵母的疫苗时要考虑的主要参数，介绍一些可用工具，并突出可能影响疫苗生产过程的主要变量。
